There has been remarkable development in “theranostics”, in which antibodies or small molecular compounds that bind to PSMA are coupled with the diagnostic emitter or therapeutic alpha- or beta-emitters to diagnose or treat prostate cancer, respectively. This evidence concerns the gene FOLH1 and Familial prostate cancer.